Scientists looking at the antiviral mechanisms of two previously identified human monoclonal antibodies have found they potently inhibit chikungunya virus (CHIKV) at multiple stages of infection. These antibodies prevent CHIKV from both entering and exiting cells, an important finding that could lead to new approaches in therapeutics and vaccines to fight infectious diseases.